What is the current valuation of the US fibromuscular dysplasia market?

The market valuation was $157.5 Million in 2024. Read More

What is the projected market size for the US fibromuscular dysplasia market by 2035?

The market is projected to reach $260.0 Million by 2035. Read More

What is the expected CAGR for the US fibromuscular dysplasia market during the forecast period 2025 - 2035?

The expected CAGR is 4.66% during the forecast period. Read More

Which company is a key player in the US fibromuscular dysplasia market?

Bristol-Myers Squibb is one of the key players in the market. Read More

What are the major segments of the US fibromuscular dysplasia market?

The major segments include Disease Type, Treatment Type, Diagnosis Method, and Age Group. Read More

What was the valuation for renal fibromuscular dysplasia in 2024?

The valuation for renal fibromuscular dysplasia was $40.0 Million in 2024. Read More

What is the projected valuation for endovascular interventions by 2035?

The projected valuation for endovascular interventions is $100.0 Million by 2035. Read More

How does the market for adult patients compare to pediatric patients in 2024?

In 2024, the market for adult patients was $90.0 Million, significantly higher than the $15.75 Million for pediatric patients. Read More

What is the valuation range for surgical interventions in the US fibromuscular dysplasia market?

The valuation range for surgical interventions is between $40.0 Million and $70.0 Million. Read More

What diagnostic method had the highest valuation in 2024?

Conventional angiography had the highest valuation, reaching $62.5 Million in 2024. Read More

US Fibromuscular Dysplasia Market

US Fibromuscular Dysplasia Market Research Report By Disease Type (Renal Fibromuscular Dysplasia, Cervical Fibromuscular Dysplasia, Carotid Fibromuscular Dysplasia, Pulmonary Fibromuscular Dysplasia), By Treatment Type (Medications, Surgical Interventions, Radiological Interventions, Endovascular Interventions), By Diagnosis Method (Ultrasound, Magnetic Resonance Angiography, Computed Tomography Angiography, Conventional Angiography) and By Age Group (Pediatric, Adult, Geriatric) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.66%

2024 Market Size

$ 157.5 Million

2035 Market Size

$ 260 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/18388-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Disease Type (USD Million)
  1. 4.1.1 Renal Fibromuscular Dysplasia
  2. 4.1.2 Cervical Fibromuscular Dysplasia
  3. 4.1.3 Carotid Fibromuscular Dysplasia
  4. 4.1.4 Pulmonary Fibromuscular Dysplasia
2. 4.2 Industrial Automation & Equipment, BY Treatment Type (USD Million)
  1. 4.2.1 Medications
  2. 4.2.2 Surgical Interventions
  3. 4.2.3 Radiological Interventions
  4. 4.2.4 Endovascular Interventions
3. 4.3 Industrial Automation & Equipment, BY Diagnosis Method (USD Million)
  1. 4.3.1 Ultrasound
  2. 4.3.2 Magnetic Resonance Angiography
  3. 4.3.3 Computed Tomography Angiography
  4. 4.3.4 Conventional Angiography
4. 4.4 Industrial Automation & Equipment, BY Age Group (USD Million)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adult
  3. 4.4.3 Geriatric
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 AstraZeneca (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bayer (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Johnson & Johnson (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DISEASE TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS METHOD
5. 6.5 US MARKET ANALYSIS BY AGE GROUP
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE TYPE, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS METHOD, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY AGE GROUP, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY AGE GROUP, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Fibromuscular Dysplasia Market Segmentation

US Fibromuscular Dysplasia Market By Disease Type (USD Million, 2025-2035)

Renal Fibromuscular Dysplasia
Cervical Fibromuscular Dysplasia
Carotid Fibromuscular Dysplasia
Pulmonary Fibromuscular Dysplasia

US Fibromuscular Dysplasia Market By Treatment Type (USD Million, 2025-2035)

Medications
Surgical Interventions
Radiological Interventions
Endovascular Interventions

US Fibromuscular Dysplasia Market By Diagnosis Method (USD Million, 2025-2035)

Ultrasound
Magnetic Resonance Angiography
Computed Tomography Angiography
Conventional Angiography

US Fibromuscular Dysplasia Market By Age Group (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”